This is from a very respectable poster on Yahoo, who just finished the CC. I will Sticky this till I hear it myself
Conference Call Highlights 1 minute ago "We have enough cash to get us into late December, CERTAINLY through the AGENDA trial. Financing as been tough, but we have been fortunate." - Ray
This is the most important thing. Shorts and manipulation will be shaken off no later than the moment the market opens after PFS data is released in "Early Q4"
Ray says that they have suspended all Genasense partnership talks until the PFS data comes out in Early Q4. I cannot stress ENOUGH to you how confident Ray is that this PFS data is going to blow this whole thing right out of the water. He says that he feels that both Genasense and Tesataxel will be pioneer drugs -- Genasense being the first melanoma drug in 40 years to be approved, and Tesataxel being the first oral taxine to hit the market.
In terms of Tesataxel partnership talks, Ray says that they are likely to partner up in Asia as there is more need for Tesataxel there.
Ray also says that there will be ANOTHER conference call around the time of the meeting. I didn't hear him clearly but I am pretty sure it is in August -- someone please confirm the actual date. He said "we hope you tune in because we are expecting to release very positive data to you".
Ray also said "I want to point out that Bristol Myers bought a melanoma drug for $2.1 Billion...and that drug is no longer active." He just implied a price on Genasense that EXCEEDS this amount.
This is amazing. This is it. Don't let the basher's get to you. The engines have started and we are FULL SPEED AHEAD to November for those results that MANY people are putting money on.
DO YOUR DD - Genasense Global Approval - 4 Billion Market Cap
Tesataxel Global Approval - At least 1 Billion Market Cap
133.7 Million Outstanding shares (multiplied by) 2 Billion Market Cap = $15
HOLD ON TIGHT!!!
Sentiment : Strong Buy
Rating :
(No ratings)Rate it:
ryjo8831
Online Now
23/Male
Massachuset...
--------------------------------------------------------------------------------
